Therapeutic novelties in migraine: new drugs, new hope?

Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial

(2018) Vladimir Skljarevski et al.   CEPHALALGIA

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine

(2018) David W Dodick et al.   CEPHALALGIA

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine

(2018) David W. Dodick et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Targeted 5-HT1F Therapies for Migraine

(2018) Marta Vila-Pueyo   Neurotherapeutics

Evaluation of Galcanezumab for the Prevention of Episodic Migraine

(2018) Virginia L. Stauffer et al.   JAMA Neurology

The Emperor’s New Gepants: Are the Effects of the New Oral CGRP Antagonists Clinically Meaningful?

(2018) Peer Tfelt-Hansen et al.   HEADACHE

Early onset of efficacy with erenumab in patients with episodic and chronic migraine

(2018) Todd Schwedt et al.   JOURNAL OF HEADACHE AND PAIN

Lasmiditan is an effective acute treatment for migraine

(2018) Bernice Kuca et al.   NEUROLOGY

Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice

(2018) Jessica C Oswald et al.   Journal of Pain Research

Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines

(2017) Joshua M. Cohen et al.   HEADACHE

Human models of migraine — short-term pain for long-term gain

(2017) Messoud Ashina et al.   Nature Reviews Neurology

Fremanezumab for the Preventive Treatment of Chronic Migraine

(2017) Stephen D. Silberstein et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Controlled Trial of Erenumab for Episodic Migraine

(2017) Peter J. Goadsby et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pathophysiology of Migraine: A Disorder of Sensory Processing

(2017) Peter J. Goadsby et al.   PHYSIOLOGICAL REVIEWS

Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab

(2017) Maria Giamberardino et al.   Journal of Pain Research

A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine

(2016) Tiffini Voss et al.   CEPHALALGIA

TEV-48125 for the preventive treatment of chronic migraine

(2016) Marcelo E. Bigal et al.   NEUROLOGY

Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine

(2015) Tony W Ho et al.   CEPHALALGIA

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

(2014) David W Dodick et al.   LANCET NEUROLOGY

Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan

(2014) Paul Rizzoli   Neuropsychiatric Disease and Treatment

Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program

(2013) Marcelo E Bigal et al.   CEPHALALGIA

Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR Review 1

(2012) Anthony J Harmar et al.   BRITISH JOURNAL OF PHARMACOLOGY

Discovery of (5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): An Oral Calcitonin Gene-Related Peptide (CGRP) Antagonist in Clinical Trials for Treating Migraine

(2012) Guanglin Luo et al.   JOURNAL OF MEDICINAL CHEMISTRY

Publication committees in clinical trials in headache

(2011) Peer Carsten Tfelt-Hansen et al.   CEPHALALGIA

Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan

(2010) David L Nelson et al.   CEPHALALGIA

What have we learnt from triggering migraine?

(2010) Henrik W Schytz et al.   CURRENT OPINION IN NEUROLOGY

PACAP38 induces migraine-like attacks in patients with migraine without aura

(2008) Henrik Winther Schytz et al.   BRAIN

The vascular theory of migraine—a great story wrecked by the facts

(2008) Peter J. Goadsby   BRAIN

Vasoactive Intestinal Peptide Causes Marked Cephalic Vasodilation, but does not Induce Migraine

(2008) A Rahmann et al.   CEPHALALGIA